Leaders in clinical and translational cancer research from academia, industry, government and the nonprofit advocacy sectors convene each spring in Bethesda, Maryland, for a unique forum designed to speed cancer treatments to patients. Our three-day, on-site interactive AAADV Workshop offers a mix of small group lectures, moderated discussions, plenary lectures and facilitated case studies of successful drug applications. Participants gain valuable insights on negotiating the spectrum of successful drug development and hone their strategic planning skills with a focus on target validation and pathway identification. The AAADV is the only workshop held in collaboration with the U.S. Food and Drug Administration designed specifically to help, participants understand and negotiate the drug development approval process so that effective cancer treatments can reach patients more quickly.
The AAADV Workshop is designed for scientists and consumer advocates with clinical trial experience interested in developing agents for the diagnosis, treatment or prevention of cancer. Individuals with limited experience in the regulatory aspects of oncology drug development will benefit from the knowledge and networking with more-experienced investigators and advocates.
Fee waivers will be available to government employees. See Registration Page for instructions.
*A limited number of scholarships will be offered to academic and patient advocate applicants. See Scholarships page for more information.
Applicants will be notified of approval within 5 [five] working days of submission of application. See Scholarships page for more information.
Full refund if cancelled by March 31, 2017. $1,450 refund if cancelled by April 21, 2017. No refund after this date.
The American Association for Cancer Research (AACR) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education activities for physicians.
AACR has designated this live activity for a maximum of 21.75 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Credit certification for individual sessions may vary, dependent upon compliance with the ACCME Accreditation Criteria. The final number of credits may vary from the maximum number indicated above.
Physicians and other health care professionals seeking AMA PRA Category 1 Credits™ for this continuing medical education activity must complete the online CME Request for Credit Survey by Friday, June 16, 2017
Certificates will only be issued to those who complete the survey. The Request for Credit Survey is available at the link below and via email.
Your CME certificate will be sent to you via email after the completion of the activity.
This course provides a comprehensive review of agent (including drugs and biological) development including pre-clinical and clinical evaluation, and regulatory procedures and endpoints required to bring discovery into clinical use that provide benefit to patients. Few individual investigators have this entire scope of this knowledge, and this workshop integrates this knowledge with real-life examples, and specifically illustrates the role that the community, including the investigator plays in the process from discovery and approvals and beyond. Only one agent is successfully produced for every 20 that enter into clinical evaluation. The workshop will impart the knowledge necessary to enable successful clinical researchers to develop the expertise in the entire spectrum of drug development by honing strategic planning skills with a focus on target validation and pathway identification that will lead to advances in the entire field of cancer research.
Following this learning activity, participants should be able to:
It is the policy of the AACR that the information presented at AACR CME activities will be unbiased and based on scientific evidence. To help participants make judgments about the presence of bias, AACR will provide information that Scientific Program Committee members and speakers have disclosed about financial relationships they have with commercial entities that produce or market products or services related to the content of this CME activity. This disclosure information will be made available in the Program/Proceedings of this workshop.
Please contact the AACR Office of CME at (215) 440-9300 or email@example.com.
"Professional societies and the advocacy community have been a fundamental component of AAADV from the beginning, creating a uniquely open environment for the discussion of problems and issues common to everyone with an interest in accelerating development of new, effective forms of cancer therapy."
Renzo Canetta, M.D.
Former Vice President, Global R&D Oncology Policy Bristol-Myers Squibb Co. Research and Development